Details:
The licensing agreement provided CSL Behring with exclusive global rights to Hemgenix (etranacogene dezaparvovec), uniQure’s first approved gene therapy for hemophilia B in the United States, EU and European Economic Area, and the UK, for patients with hemophilia B.
Lead Product(s): Etranacogene Dezaparvovec-drlb
Therapeutic Area: Genetic Disease Product Name: Hemgenix
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CSL Behring
Deal Size: $2,050.0 million Upfront Cash: $450.0 million
Deal Type: Licensing Agreement June 20, 2023
Details:
The divestment aims to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of Hemgenix (etranacogene dezaparvovec-drbl), the first and only FDA-approved gene therapy for hemophilia B, to HealthCare Royalty and Sagard Healthcare.
Lead Product(s): Etranacogene Dezaparvovec-drbl
Therapeutic Area: Genetic Disease Product Name: Hemgenix
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: HealthCare Royalty
Deal Size: $400.0 million Upfront Cash: $400.0 million
Deal Type: Divestment May 15, 2023
Details:
Hemgenix (Etranacogene dezaparvovec), is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds after a single infusion.
Lead Product(s): Etranacogene Dezaparvovec-drlb
Therapeutic Area: Genetic Disease Product Name: Hemgenix
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
Under the terms of the agreement, NewBridge will work closely with Pharming to provide access for RUCONEST® for the treatment of acute hereditary angioedema (“HAE”) in MENA.
Lead Product(s): Conestat Alfa
Therapeutic Area: Genetic Disease Product Name: Ruconest
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: NewBridge Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2021